Neonc Technologies (NASDAQ:NTHI) Upgraded at Zacks Research

Zacks Research upgraded shares of Neonc Technologies (NASDAQ:NTHI) to a hold rating in a research report released on Wednesday morning,Zacks.com reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neonc Technologies in a research report on Monday, December 29th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce”.

Neonc Technologies Price Performance

Shares of NASDAQ:NTHI opened at $8.73 on Wednesday. The stock has a 50 day moving average price of $8.74 and a 200-day moving average price of $8.12. Neonc Technologies has a 52-week low of $3.20 and a 52-week high of $25.00.

Neonc Technologies (NASDAQ:NTHI) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter.

Insider Activity at Neonc Technologies

In other news, President Amir F. Heshmatpour purchased 24,000 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The stock was bought at an average cost of $6.07 per share, with a total value of $145,680.00. Following the completion of the purchase, the president owned 2,986,000 shares in the company, valued at approximately $18,125,020. This represents a 0.81% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have bought 31,100 shares of company stock worth $192,099.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. LVW Advisors LLC purchased a new stake in shares of Neonc Technologies in the second quarter valued at approximately $108,000. HCR Wealth Advisors purchased a new position in Neonc Technologies during the 2nd quarter worth $54,000. Royal Bank of Canada bought a new stake in Neonc Technologies during the 1st quarter valued at $247,000. Bank of America Corp DE bought a new stake in Neonc Technologies during the 2nd quarter valued at $801,000. Finally, Vanguard Group Inc. purchased a new stake in shares of Neonc Technologies in the 3rd quarter worth $1,279,000.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.